Remibrutinib new option beyond antihistamines for managing chronic spontaneous urticaria

Key points of this study include:

• One hundred ninety-four patients entered the treatment period and received ≥ 1 dose of remibrutinib.
• The overall safety profile was comparable between the extension and core studies.
• Mild to moderate treatment-emergent adverse events (TEAEs) were reported mostly. According to investigators, these were unrelated to remibrutinib.
• Infections of skin and subcutaneous tissue and gastrointestinal disorders were the three most common TEAEs, constituting 30.9 %, 26.8 % and 16.5 %, respectively.
• At weeks 4 and 52, mean±standard deviation change from baseline in UAS7 was −17.6±13.40 and −21.8±10.70; UAS7=0 was achieved in 28.2% and 55.8%, and UAS7≤6 in 52.7% and 68.0% of patients, respectively.

Long-term exposure of remibrutinib demonstrated consistent favorable safety, with fast and sustained efficacy for up to 52 weeks in CSU patients.

They said Remibrutinib has the potential to become a new oral therapeutic option for managing patients with CSU inadequately controlled with H1-antihistamines.

As acknowledged, the study was funded by Novartis Pharma AG, Basel, Switzerland.

Reference:

Jain, V. et al. Remibrutinib demonstrates a favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks. The Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2023.10.007